Wed. 7 Feb 2024, 8:01am ET
Benzinga
Biotech, News, General
Enlivex Therapeutics Ltd., (NASDAQ:ENLV, the "Company"))))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering AllocetraTM, the Company's immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United States for the product's composition and manufacturing method.